Xiangxue Pharmaceutical (300147) — Free Cash Flow Generation Index
Xiangxue Pharmaceutical (300147) has a Free Cash Flow Generation Index of 0.92x as of September 2025. Free cash flow of CN¥69.90 Million represents 1% of operating cash flow (CN¥75.64 Million). Explore Xiangxue Pharmaceutical capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Xiangxue Pharmaceutical Free Cash Flow Generation Index (2007–2025)
Historical FCF Generation Index trend for Xiangxue Pharmaceutical across 19 annual periods. For the full cash flow conversion analysis, see Xiangxue Pharmaceutical operating cash flow efficiency.
Annual Free Cash Flow Generation for Xiangxue Pharmaceutical (2007–2025)
Year-by-year Free Cash Flow Generation Index for Xiangxue Pharmaceutical. Check Xiangxue Pharmaceutical investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (CNY) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.85x | CN¥118.12 Million | CN¥139.63 Million | CN¥21.51 Million | ▲ +190.1% |
| 2024 | -0.94x | CN¥-17.07 Million | CN¥18.17 Million | CN¥35.24 Million | ▼ -219.3% |
| 2023 | 0.79x | CN¥207.41 Million | CN¥263.44 Million | CN¥56.03 Million | ▲ +228.0% |
| 2022 | -0.62x | CN¥-139.89 Million | CN¥227.38 Million | CN¥367.27 Million | ▲ +48.1% |
| 2021 | -1.18x | CN¥-305.18 Million | CN¥257.56 Million | CN¥562.74 Million | ▲ +32.3% |
| 2020 | -1.75x | CN¥-450.24 Million | CN¥257.18 Million | CN¥707.42 Million | ▲ +74.9% |
| 2019 | -6.96x | CN¥-578.07 Million | CN¥83.02 Million | CN¥661.09 Million | ▼ -57.2% |
| 2018 | -4.43x | CN¥-404.23 Million | CN¥91.24 Million | CN¥495.46 Million | ▲ +27.4% |
| 2017 | -6.10x | CN¥-668.33 Million | CN¥109.53 Million | CN¥777.87 Million | ▲ +31.5% |
| 2016 | -8.91x | CN¥-1.77 Billion | CN¥198.48 Million | CN¥1.97 Billion | ▼ -1116.4% |
| 2015 | -0.73x | CN¥-117.06 Million | CN¥159.89 Million | CN¥276.95 Million | ▼ -54.9% |
| 2014 | -0.47x | CN¥-78.27 Million | CN¥165.58 Million | CN¥243.85 Million | ▼ -1681.0% |
| 2013 | 0.03x | CN¥9.82 Million | CN¥328.37 Million | CN¥318.55 Million | ▲ +101.2% |
| 2012 | -2.52x | CN¥-299.22 Million | CN¥118.91 Million | CN¥418.12 Million | ▲ +63.0% |
| 2011 | -6.81x | CN¥-201.13 Million | CN¥29.55 Million | CN¥230.69 Million | ▼ -2614.0% |
| 2010 | -0.25x | CN¥-11.40 Million | CN¥45.47 Million | CN¥56.87 Million | ▼ -73.6% |
| 2009 | -0.14x | CN¥-6.67 Million | CN¥46.19 Million | CN¥52.86 Million | ▲ +90.2% |
| 2008 | -1.47x | CN¥-81.99 Million | CN¥55.72 Million | CN¥137.71 Million | ▼ -2924.4% |
| 2007 | -0.05x | CN¥-6.71 Million | CN¥138.02 Million | CN¥144.73 Million | — |